---
document_datetime: 2026-02-17 10:46:43
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/trecondi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: trecondi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.7789288
conversion_datetime: 2026-02-21 13:09:17.811701
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Trecondi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 13/01/2026                          |                                             | SmPC                             |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000313406   | PRODUCTS - C.I.z Other variation - Accepted To correct the in vitro DDI conclusion in SmPC section 5.2 in accordance with the information in Module 4.2.2.6 as approved. In addition the SmPC section 4.5 has been updated with the active substance used for reference.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------------|
| Variation type IB / | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.e Minor change to the restricted part of an Active Substance Master File - Accepted B.I.d.1.a Re-test period/storage period - | 24/07/2025 | EMA/VR/0000272669 |

<div style=\"page-break-after: always\"></div>

| test period/storage period supported by real time data - Accepted   |
|---------------------------------------------------------------------|